In addition, the anti-inflammatory and immunoregulatory effect of orally administered GMP on experimental colitis models has been associated with down-regulation of TGF-β expression in colonic tissue, but also with an increase in TGF-β-mediated signaling [61,62]. This evidence concerns the gene TGFB1 and colitis.